ABCB11 and cholestasis: Given the potential of BSEP inhibitors to cause cholestasis and DILI, the aim of the present study was to develop a physiologically based kinetic (PBK) modeling facilitated approach linked with Markov Chain Monte Carlo simulations, that would provide a tool to predict dose-dependent BA accumulation in humans upon treatment with a BSEP inhibitor.